Cite
HARVARD Citation
Koh, C. et al. (n.d.). Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet infectious diseases. 15 (10), pp. 1167-1174. [Online].